CoChat
Sign Up
Cited by 308Diabetes Treatment and ManagementDiabetes Management and ResearchPeptidase Inhibition and Analysis

The DOI matches its Crossref record; 115 of the 121 references it cites were found in a registry or an index.

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

Open access
Richter, Bernd, Bandeira-Echtler, Elizabeth, Bergerhoff, Karla, Lerch, Christian·2008·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd006739.pub2PMC PMC8985075
Open this paper in CoChat — free account

Abstract

BACKGROUND: In type 2 diabetes mellitus there is a progressive loss of beta-cell function. One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin and vildagliptin. OBJECTIVES: To assess the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. SEARCH STRATEGY: Studies were obtained from computerised searches of MEDLINE, EMBASE and The Cochrane Library. SELECTION CRITERIA: Studies were included if they were randomised controlled trials in adult people with type 2 diabetes mellitus and had a trial duration of at least 12 weeks. DATA COLLECTION AND ANALYSIS: Two authors independently assessed risk of bias and extracted data. Pooling of studies was performed by means of fixed-effect meta-analysis. MAIN RESULTS: Twenty-five studies of good quality were identified, 11 trials evaluated sitagliptin and 14 trials vildagliptin treatment. Altogether, 6743 patients were randomised in sitagliptin and 6121 patients in vildagliptin studies, respectively. Sitagliptin and vildagliptin studies ranged from 12 to 52 weeks duration. No data were published on mortality, diabetic complications, costs of treatment and health-related quality of life. Sitagliptin and vildagliptin therapy in comparison with placebo resulted in an HbA1c reduction of approximately 0.7% and 0.6%, respectively. Data on comparisons with active comparators were limited but indicated no improved metabolic control following DPP-4 intervention in contrast to other hypoglycaemic agents. Sitagliptin and vildagliptin therapy did not result in weight gain but weight loss was more pronounced following placebo interventions. No definite conclusions could be drawn from published data on sitagliptin and vildagliptin effects on measurements of beta-cell function. Overall, sitagliptin and vildagliptin were well tolerated, no severe hypoglycaemia was reported in patients taking sitagliptin or vildagliptin. All-cause infections increased significantly after sitagliptin treatment but did not reach statistical significance following vildagliptin therapy. All published randomised controlled trials of at least 12 weeks treatment with sitagliptin and vildagliptin only reported routine laboratory safety measurements AUTHORS' CONCLUSIONS: DPP-4 inhibitors have some theoretical advantages over existing therapies with oral antidiabetic compounds but should currently be restricted to individual patients. Long-term data especially on cardiovascular outcomes and safety are urgently needed before widespread use of these new agents. More information on the benefit-risk ratio of DPP-4 inhibitor treatment is necessary especially analysing adverse effects on parameters of immune function. Also, long-term data are needed investigating patient-oriented parameters like health-related quality of life, diabetic complications and all-cause mortality.

Overview

Integrity signals

Registry

Crossref · 10.1002/14651858.cd006739.pub2

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

2 retracted

Research works printed but not linked: 7

  1. Mimori, 2006, Vildagliptin improves glucose control as evidenced by HbA1c after 12 weeks in Japanese patients with type 2 diabetes, Diabetes, 55(suppl 1), A125
  2. Nonaka, 2006, Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-IV inhibitor, in Japanese patients with T2DM, Diabetes, 55(suppl 1), A129
  3. Canadian Agency for Drugs and Technologies in Health, 2006, Vildagliptin (Structured abstract), Ottawa : Canadian Agency for Drugs and Technologies in Health
  4. Drucker, 2007, Sitagliptin, Nature Reviews, Drug Discovery., 109
  5. Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd
  6. Kahn, 1997, The pathophysiology of type II (noninsulindependent) diabetes mellitus: implications for treatment
  7. Schlesselman, 2006, Vildagliptin: A dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes, Formulary, 41, 494

Cited by

Sorted by citations

See all 308

Related

See all

Metadata

Authors
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C.
Affiliations
Düsseldorf University Hospital (DE)
ORCID
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2008-04-23
Volume
2010
Issue
1
Pages
CD006739-CD006739
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd006739.pub2
PMC
PMC8985075
OpenAlex
W1916480346
Cited by
308
References
121
Citations by year
2026: 2 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 9 · 2021: 7 · 2020: 15 · 2019: 13 · 2018: 9 · 2017: 9 · 2016: 16 · 2015: 27 · 2014: 18 · 2013: 33 · 2012: 30
FWCI
4.84
Type
journal article
Language
en
Open access
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Keywords
type 2 diabetes, sitagliptin, vildagliptin, glycemic control, HbA1c, beta-cell function, weight change, hypoglycemia, infection, drug safety, oral antidiabetic drugs, GLP-1 receptor agonists, treatment costs, health-related quality of life
MeSH terms
Sitagliptin Phosphate, Vildagliptin, Adamantane, Diabetes Mellitus, Type 2, Humans, Nitriles, Pyrazines, Pyrrolidines, Triazoles, Randomized Controlled Trials as Topic, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review